Hoenig Michel R, Kostner Karam M, Read Stephen J, Walker Philip J, Atherton John J
Department of Cardiology, Royal Brisbane & Women's Hospital, Herston, QLD 4029, Brisbane, Australia.
Endocr Metab Immune Disord Drug Targets. 2007 Sep;7(3):153-66. doi: 10.2174/187153007781662567.
Obesity and the metabolic syndrome are becoming one of the biggest health challenges of the 21(st) century. Cholesterol metabolism is significantly altered in both obesity and metabolic syndrome in that cholesterol synthesis is increased and absorption reduced and this has important implications for the treatment of lipid disorders in both obesity and the metabolic syndrome. In the present review we discuss these changes in detail especially in the context of a more standardized approach for cholesterol reduction like the TARGET LDL trial. Customized care is topical in lipidology as we strive to achieve LDL cholesterol and non-HDL cholesterol targets in every patient.
肥胖和代谢综合征正成为21世纪最大的健康挑战之一。肥胖和代谢综合征患者的胆固醇代谢均发生显著改变,表现为胆固醇合成增加而吸收减少,这对肥胖和代谢综合征患者脂质紊乱的治疗具有重要意义。在本综述中,我们将详细讨论这些变化,尤其是在采用更标准化的降胆固醇方法(如TARGET LDL试验)的背景下。由于我们努力使每位患者都达到低密度脂蛋白胆固醇(LDL-C)和非高密度脂蛋白胆固醇(non-HDL-C)目标,个性化治疗在脂质学领域备受关注。